COVID-19 and Diarylamidines: The Parasitic Connection
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hulme, John | - |
dc.date.accessioned | 2023-05-05T01:40:32Z | - |
dc.date.available | 2023-05-05T01:40:32Z | - |
dc.date.created | 2023-04-04 | - |
dc.date.issued | 2023-04 | - |
dc.identifier.issn | 1422-0067 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/87552 | - |
dc.description.abstract | As emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants (Omicron) continue to outpace and negate combinatorial vaccines and monoclonal antibody therapies targeting the spike protein (S) receptor binding domain (RBD), the appetite for developing similar COVID-19 treatments has significantly diminished, with the attention of the scientific community switching to long COVID treatments. However, treatments that reduce the risk of “post-COVID-19 syndrome” and associated sequelae remain in their infancy, particularly as no established criteria for diagnosis currently exist. Thus, alternative therapies that reduce infection and prevent the broad range of symptoms associated with ‘post-COVID-19 syndrome’ require investigation. This review begins with an overview of the parasitic–diarylamidine connection, followed by the renin-angiotensin system (RAS) and associated angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSSR2) involved in SARS-CoV-2 infection. Subsequently, the ability of diarylamidines to inhibit S-protein binding and various membrane serine proteases associated with SARS-CoV-2 and parasitic infections are discussed. Finally, the roles of diarylamidines (primarily DIZE) in vaccine efficacy, epigenetics, and the potential amelioration of long COVID sequelae are highlighted. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | International Journal of Molecular Sciences | - |
dc.title | COVID-19 and Diarylamidines: The Parasitic Connection | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000970235900001 | - |
dc.identifier.doi | 10.3390/ijms24076583 | - |
dc.identifier.bibliographicCitation | International Journal of Molecular Sciences, v.24, no.7, pp.1 - 21 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85152345844 | - |
dc.citation.endPage | 21 | - |
dc.citation.startPage | 1 | - |
dc.citation.title | International Journal of Molecular Sciences | - |
dc.citation.volume | 24 | - |
dc.citation.number | 7 | - |
dc.contributor.affiliatedAuthor | Hulme, John | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | diarylamidines | - |
dc.subject.keywordAuthor | long COVID | - |
dc.subject.keywordAuthor | serine protease | - |
dc.subject.keywordPlus | DIMINAZENE ACETURATE | - |
dc.subject.keywordPlus | TRYPANOSOMA-CRUZI | - |
dc.subject.keywordPlus | OLIGOPEPTIDASE-B | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | DRUG | - |
dc.subject.keywordPlus | SITE | - |
dc.subject.keywordPlus | STIMULATION | - |
dc.subject.keywordPlus | CONGOLENSE | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | BABESIOSIS | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.